Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series. (21st December 2018)

• Record Type: Journal Article
• Authors: Wegner, Rodney E; Ahmed, Nissar; Hasan, Shaakir; Schumacher, Lana Y; Colonias, Athanasios
• Is Part Of: Lung cancer management. Volume 7:Number 3(2018)
• Publication Date: 2018-12-21
• Subjects: brachytherapy -- lung cancer -- radiofrequency ablation -- SBRT -- vicryl mesh; Lungs -- Cancer -- Periodicals; 616.99424
• DOI: 10.2217/lmt-2018-0012
• Languages: English
• ISSNs: 1758-1966

Abstract

Aim: Non-small-cell lung cancer recurs locally 10–40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients.Methods: We identified and reviewed clinical outcomes in ten patients with recurrent non-small-cell lung cancer after past vicryl mesh brachytherapy.Results: Ten patients with a median age of 77 were treated to a median dose of 48 Gy in five fractions. Local control at 1 year was 88%. There was one distant failure at 29 months. There was no significant toxicity after SBRT.Conclusion: SBRT is safe and effective when used for re-irradiation after past ablative therapies.